Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients

Liver International

Volumn 35, Issue 9, 2015, Pages 2090-2099

  Miailhes, Patrick ^a   Gilbert, Camille ^b   Lacombe, Karine ^c,d   Arends, Joop E ^e   Puoti, Massimo ^f   Rockstroh, Jürgen K ^g   Sogni, Philippe ^h,i   Fontaine, Hélène ^h,i   Rosenthal, Eric ^j   Winnock, Maria ^b   Loko, Marc Arthur ^b   Wittkop, Linda ^b,k   Dabis, François ^b,k   Salmon, Dominique ^h  

^a CROIX ROUSSE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f Institut of Infectious Diseases   (Italy)

^g UNIVERSITY OF BONN   (Germany)

^h Institut Cochin   (France)

ⁱ INSTITUT COCHIN   (France)

^j CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Boceprevir; Cirrhosis; HIV HCV genotype 1 coinfection; Telaprevir

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FRANCE; GERMANY; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INVESTIGATIVE PROCEDURES; ITALY; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME;

ANEMIA; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; ITALY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; PROLINE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84938978481     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12799     Document Type: Article

References (27)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa - 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment durat ion and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
3. Mc Hutchinson JG, Lawitz EJ, Schiffman ML, et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for treatment of Hepatitis C Infection. N Engl J Med 2009; 361: 580-93.
4. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized contro lled trial. JAMA 2004; 292: 2839-48.
5. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
6. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
7. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa -2b plus ribavirin for treatment of HIV/HCV-coinfected patients. AIDS 2004; 18: F27-36.
8. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
9. Sulkowski M, Sherman K, Dieterich D, et al. Telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1 infection in HIV-infected patients. Ann Intern Med 2013; 159: 86-96.
10. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
11. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
12. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
13. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
14. Poizot-Martin I, Bellissant E, Colson P, et al. ANRS-HC27 Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; abstract 659LB.
15. Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV/Hepatitis C virus_coinfected patients failing treatment with pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59: 1768-76.
16. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-42.
17. Mira JA, Garcia-Rey S, Rivero A, et al. Response to Pegylated Interferon plus Ribavirin among HIV/Hepatitis C Virus - coinfected patients with compensated liver cirrhosis. Clin Infect Dis 2012; 55: 1719-26.
18. Colombo M, Strasser S, Moreno C, et al. Sustained virological response with telaprevir in 1, 078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol 2014; 61: 976-83.
19. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 2014; 61: 200-9.
20. Lacombe K, Valin N, Stittou H, et al. Efficacy and tolerance of telaprevir in HIV-HCV genotype 1 co-infected patients failing previous anti-HCV therapy: 24-week results. AIDS 2013; 27: 1356-9.
21. Genebat M, Vera F, Hernandez-Quero J, et al. Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Res 2014; 104: 59-61.
22. Poordad F, Lawitz E, Reddy KR, et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection-a randomized trial. Gastroenterology 2013; 145: 1035-44.
23. Virlogeux V, Pradat P, Bailly F, et al. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat 2014; 21: e98-107.
24. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
25. Poizot-Martin I, Gilbert C, Carrieri P et al. Access to HCV triple therapy with telaprevir or boceprevir in real-life setting in HIV-HCV co-infected patients - ANRS CO13 Hepavih Cohort. 7th IAS conference on HIV pathogenesis, treatment and prevention, 30 June-3 July 2013, Kuala Lumpur, Malaysia; abs TUABO102.
26. Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56: 1646-53.
27. Sarkar S, Kim JK. Advance in interferon-free hepatitis C therapy: 2014 and beyond. Hepatology 2014; 59: 1641-4.